Mirador Therapeutics, the secretive immune disease biotech with more than $650 million in VC funding, is finally revealing a piece of its pipeline. The San Diego biotech said Thursday it reached a deal for worldwide …
Source: Endpoints News
You may also like
KRAS-Targeted Vaccine Crosses First Clinical Milestone...
Gene Therapy Partners Aim to Enhance Protein Expression
Modular Antibody–ADC Click Chemistry Overcomes Tumor...
See, Blind Mice: Consortium’s Drugs Restore Sight
Genetic Study Links Excessive Sweating to Neurological...
Parkinson’s in the Clinic, Insilico enters Phase...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.